--- title: "enGene Holdings (now enGene Therapeutics) sets up $100,000,000 stock program" url: "https://aibio.space/news/engene-holdings-now-engene-therapeutics-sets-up-100-000-000-stock/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-03-09" section: "Financings" tickers: "NASDAQ:ENGN" source: "https://www.sec.gov/Archives/edgar/data/1980845/000119312526097546/engn-20260309.htm" summary: "The company signed a sales agreement with Leerink Partners LLC on March 9, 2026. It ended an earlier agreement with Jefferies LLC under which no shares wer" --- By the aibio.space news desk. Sources - [enGene Therapeutics Inc. 8-K (2026-03-09)](https://www.sec.gov/Archives/edgar/data/1980845/000119312526097546/engn-20260309.htm) - [copy_of_engene_prosupp_a.htm](https://www.sec.gov/Archives/edgar/data/1980845/000119312526097563/copy_of_engene_prosupp_a.htm) - [enGene Therapeutics Inc. 10-K (2025-12-22): business](https://www.sec.gov/Archives/edgar/data/1980845/000119312525328743/engn-20251031.htm) - [enGene Therapeutics Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1980845/000119312525328743/) [ENGN](https://aibio.space/companies/engene-therapeutics/) 2026-03-09 # enGene Holdings (now enGene Therapeutics) sets up $100,000,000 stock program Tickers [ENGN](https://aibio.space/companies/engene-therapeutics/) The company signed a sales agreement with Leerink Partners LLC on March 9, 2026. It ended an earlier agreement with Jefferies LLC under which no shares were sold. ## Key facts - **Company**: enGene Therapeutics Inc. (NASDAQ: ENGN) - **News type**: Financings - **Primary source**: [enGene Therapeutics Inc. 8-K (2026-03-09)](https://www.sec.gov/Archives/edgar/data/1980845/000119312526097546/engn-20260309.htm) *The New York Stock Exchange trading floor. Photo: Carol M. Highsmith, public domain, via Wikimedia Commons. The picture shows the field, not the companies named.* ## The new sales agreement enGene Holdings Inc., now enGene Therapeutics Inc. (Nasdaq: [ENGN](https://aibio.space/companies/engene-therapeutics/)), signed a sales agreement with Leerink Partners LLC on March 9, 2026. Under it the company may sell common shares with an aggregate offering price of up to $100,000,000 from time to time. Leerink is the sales agent and may sell by any method that counts as an at-the-market offering under the securities rules, or by any other method the law permits. It uses commercially reasonable efforts and follows the company's limits on price, time and size, but it is not required to sell any specific amount. The company will pay Leerink a commission of up to 3.0% of the gross proceeds of shares sold. It will also reimburse certain expenses and give Leerink customary indemnification and contribution rights. No shares will be sold in Canada or to a person resident there. The legal opinion on the shares is from Blake, Cassels & Graydon LLP and is filed as Exhibit 5.1. The base prospectus says legal matters on the securities will be passed upon for the company by Blake, Cassels & Graydon LLP on Canadian law and Morgan, Lewis & Bockius LLP on U.S. law. The filings name no counsel for Leerink. ## The Jefferies agreement On February 27, 2026, the company gave Jefferies LLC written notice that it was ending the Open Market Sale Agreement dated December 20, 2024. The termination took effect March 6, 2026. No shares were sold under that agreement, and the company says it owes no termination penalty. Jefferies had been the sales agent under that earlier program. ## Dilution and the share count The prospectus supplement counts 66,989,466 common shares outstanding as of March 5, 2026. It excludes 12,076,920 common shares issuable on exercise of outstanding options. The last reported sale price on the Nasdaq Capital Market on March 5, 2026 was $8.71 per share. At that price, the supplement assumes sales of 11,481,056 shares and shows 78,470,522 shares outstanding immediately after the offering. The supplement says the actual number will vary with the price at which shares are sold. The offering is an at-the-market program, so there is no fixed block of new stock. The company can sell into the market over time, and each sale adds to the share count. ## The product and the money The company says the net proceeds will go primarily to the clinical development of detalimogene and to general corporate purposes. Detalimogene is a non-viral genetic medicine built on the company's chitosan-based gene delivery platform. Its first target is non-muscle invasive bladder cancer. The drug is being tested in a combined Phase 1/2 open-label trial called LEGEND, and the Phase 2 portion covers several cohorts of high-risk patients. The supplement describes BCG, the established first-line therapy, as one in which many patients see recurrence that does not respond to more BCG, and it cites a prolonged BCG shortage in the United States. The supplement reports no efficacy results from LEGEND. The annual report for the year ended October 31, 2025 shows research and development expense of $94.5 million, up from $38.3 million a year earlier. The net loss was $117.3 million, against $55.1 million. Cash used in operations was $99.2 million, against $48.3 million. At October 31, 2024, the company held $173.0 million in cash and cash equivalents and $65.3 million in short-term investments, a balance more than a year older than the sales agreement. The sales agreement adds a source of equity that the company can draw on as its share price moves. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story ENGN enGene Therapeutics Inc. NASDAQ ยท Canada Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/engene-holdings-now-engene-therapeutics-sets-up-100-000-000-stock/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "enGene Holdings (now enGene Therapeutics) sets up $100,000,000 stock program", 2026-03-09, https://aibio.space/news/engene-holdings-now-engene-therapeutics-sets-up-100-000-000-stock/